Hi all, Today we released Imagion’s Appendix 4D and Financial...

Hi all,

Today we released Imagion’s Appendix 4D and Financial Results for the period ended 30 June 2021.

In the first half of 2021 we have maintained a healthy balance sheet while making significant strides in our first-ever human clinical trial for our MagSense® technology.

Additionally we initiated new important collaborations with Patrys Limited and Monash University to explore the use of our nanoparticles in the diagnosis of brain cancers and prostate cancer, respectively. Subsequent to the close of the first half we announced a Joint Development Agreement with Global Cancer Technology to develop nanocrystals for the treatment of breast cancer.

We appreciate your ongoing support for our company.

You can read our Half Year Report here.